Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP
NCT ID: NCT04735588
Last Updated: 2022-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
140 participants
OBSERVATIONAL
2022-08-22
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation on a Dynamic Cohort of Italian Patients With Active ITP
NCT03465020
COVID19-hematological Malignancies: the Italian Hematology Alliance
NCT04352556
Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
NCT01196884
The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP
NCT03377439
Biologic Characterization of Patients With ITP
NCT05694325
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosed of ITP (ITP could be past, ongoing, persistent \>3 months, chronic \>12 months) in patients that are in regular follow-up (at least once a year) and who have been diagnosed with COVID-19
* All patients who develop de novo ITP from 1st January 2020 to the end of study after a diagnosis of COVID-19 or during the first 6 months after COVID-19 recovery
* Signed informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gruppo Italiano Malattie EMatologiche dell'Adulto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ASST Degli Spedali Civili Di Brescia - UO Ematologia
Brescia, , Italy
Unità di Onco-Ematologia - Azienda Ospedaliera Garibaldi
Catania, , Italy
A.O.U. Careggi - Ematologia
Florence, , Italy
AOU San Luigi Gonzaga - SCDU Ematologia Generale E Oncoematologia
Orbassano, , Italy
Policlinico Universitario Agostino Gemelli
Roma, , Italy
Ematologia Città della Salute e della Scienza di Torino - Molinette
Torino, , Italy
ASST Dei Sette Laghi - UOC Ematologia
Varese, , Italy
AOU Integrata Di Verona, Policlinico G.B. Rossi - UOC Ematologia
Verona, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mariella D'Adda
Role: primary
Ugo Consoli
Role: primary
Valentina Carrai
Role: primary
Alessandro Morotti
Role: primary
Elena Rossi
Role: primary
Alessandra Borchiellini
Role: primary
Domenica Caramazza
Role: primary
Carlo Visco
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ITP1021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.